Third consensus on medical treatment of metastatic breast cancer

Beslija, S.; Bonneterre, Jacques; Burstein, Harold J.; Cocquyt, Véronique; Gnant, Michael; Goodwin, Pamela J.; Heinemann, Volker; Jassem, Jacek; Köstler, Wolfgang J.; Krainer, Michael; Ménard, Sylvie; Petit, Thierry; Petruželka, Luboš; Possinger, K.; Schmid, Peter; Stadtmauer, E.; Stockler, Martin R.; Belle, Simon Van; Vogel, Charles L.; Wilcken, Nicholas; Wiltschke, Christoph; Zielinski, Christoph; Zwierzina, Heinz

doi:10.1093/annonc/mdp261

Cited by 180 publications

(99 citation statements)

References 170 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…92 Despite significant progress in screening and early detection, many patients experience local or regional recurrence, metastasis, and resistance to conventional chemotherapies. 93,94 Numerous studies have elucidated some of the many mechanisms of drug resistance in breast cancer. 95 TNF-related apoptosis-inducing ligand (TRAIL), a member of the tumor necrosis family, is an integral initiator of the extrinsic apoptosis pathway.…”

Section: Breast Cancermentioning

confidence: 99%

LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential

Zhang

et al. 2015

Cancer Biology & Therapy

103

View full text Add to dashboard Cite

Section: Breast Cancermentioning

confidence: 99%

LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential

Zhang

et al. 2015

Cancer Biology & Therapy

103

View full text Add to dashboard Cite

“…The goal of any treatment in this scenario is disease control, palliation of symptoms, and maintenance of the highest quality of life [4]. About one third of patients with MBC present with a local or regional recurrence involving lymph nodes and/or the chest wall.…”

Section: Introductionmentioning

confidence: 99%

Symptom Management in Metastatic Breast Cancer

2011

View full text Add to dashboard Cite

Approximately 40,000 women die as a result of breast cancer each year and many more live with advanced disease. When breast cancer recurs, the goals of treatment often shift from one of cure to controlling the disease for as long as possible while palliating symptoms interfering with the patient's functional status and quality of life. This requires ongoing discussions with the patient and family about the goals of care. Many symptoms depend on the site of metastasis, with bone being the most frequent, and commonly occur with fatigue, depression, insomnia, and pain. The purpose of this paper is to identify and provide an overview of the management of the most common symptoms in patients with breast cancer metastases.

show abstract

“…A recent consensus paper reported that multiple factors including HER2 status, site/extent of recurrence or metastasis, DFS, and adjuvant treatments are effective in patients' prognosis (32,33).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Factors of Recurrence (Early and Late) and Death in Breast Cancer Patients in Iranian Women

Akbari

Nafissi

et al. 2016

Iran J Cancer Prev

View full text Add to dashboard Cite

show abstract

Third consensus on medical treatment of metastatic breast cancer

Abstract: The present consensus manuscript updates evidence-based recommendations for state-of-the-art treatment of MBC depending on disease-associated and biological variables.

Cited by 180 publications

References 170 publications

LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential

LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential

Symptom Management in Metastatic Breast Cancer

Prognostic Factors of Recurrence (Early and Late) and Death in Breast Cancer Patients in Iranian Women

Contact Info

Product

Resources

About